{"abstract":"<RM>This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the inventions embodied in U.S. Patent Application S/N 08/533,895, filed on September 26, 1995, entitled \"MHC Class II Restricted Melanoma Antigens and Their Use in Therapeutic Methods\", to Therion Biologics Corporation of Cambridge, Massachusetts. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory will be worldwide and the field of use may be limited to recombinant poxvirus-based vaccines for human cancer immunotherapy, said poxviruses encoding Class II- restricted melanoma antigens, or modifications, derivatives, or immunogenic peptides thereof, and vaccination protocols comprising the administration of one or more Class II-restricted melanoma peptides in addition to a recombinant poxvirus-based vaccine (for example, in a prime and boost protocol), but specifically excluding the use of these peptides in any context other than a recombinant poxvirus-based vaccination protocol.","action":"<RM>Notice","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2001/04/30/01-10578.html","cfr_references":[],"citation":"66 FR 21406","comment_url":null,"comments_close_on":"2001-06-29","correction_of":null,"corrections":[],"dates":"<RM>Only written comments and/or license applications which are received by the National Institutes of Health on or before June 29, 2001 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"01-10578","effective_on":null,"end_page":21407,"executive_order_notes":null,"executive_order_number":null,"explanation":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2001/04/30/01-10578.xml","html_url":"https://www.federalregister.gov/documents/2001/04/30/01-10578/prospective-grant-of-exclusive-license-mhc-class-ii-restricted-melanoma-antigens-and-their-use-in","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/01-10578?publication_date=2001-04-30","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2001-04-30/01-10578/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":12,"last_updated":"2026-04-05 08:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2001-04-30/pdf/01-10578.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":null,"publication_date":"2001-04-30","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2001/04/30/01-10578.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2011-02-27T17:37:38Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":21406,"subtype":null,"title":"Prospective Grant of Exclusive License: MHC Class II Restricted Melanoma Antigens and Their Use in Therapeutic Methods","toc_doc":"Therion Biologics Corp.","toc_subject":"Patent licenses; non-exclusive, exclusive, or partially exclusive:","topics":[],"type":"Notice","volume":66}